Meiji Pharma Spain

What Meiji Pharma Spain does

Meiji Pharma Spain, S.A. is a Spanish pharmaceutical manufacturer and wholly-owned subsidiary of Japan's Meiji Seika Pharma Co., Ltd. (the pharmaceutical division of Meiji Holdings Co., Ltd.), founded in 1991 and headquartered in Alcalá de Henares, Madrid, with 251-500 employees. The company operates two dedicated manufacturing plants on a 56,000 m2 site, one specialized in cephalosporin antibiotics (Cefditoren Pivoxil) and one general plant for non-antibiotic production, with 11,000 m2 of built area, an 8,200-pallet validated warehouse including 185 pallets of cold storage, and a portfolio of antibiotics, sterile injectables (ampoules, pre-filled syringes, eye drops), oral solids, and medical devices. It holds simultaneous GMP certifications from EU GMP, US FDA, ANVISA (Brazil), PMDA (Japan), and ISO 13485, enabling export to more than 25 countries for pharmaceutical products and more than 45 countries for intra-articular hyaluronic acid devices.

The company's product portfolio spans proprietary branded prescription medicines (Meiact/Spectracef with Cefditoren, Dagan/Zolpidem, Escitalopram, Lornoxicam, Presar/Valsartan, Profer, Vysribli/Denosumab, Acyclovir), intra-articular hyaluronic acid medical devices (Adant, Viscoartro), ophthalmic viscosurgical devices (Supralon 1%, 1.4%, 2%, 3% Dispersive), and a hospital disinfection line (ADASPOR, PERASAFE, ISACLEAN, BACTRYL, VIRKON). Manufacturing technology includes fluid-bed granulation and drying, terminal sterilization, aseptic filling, four blister lines with serialization/anti-counterfeiting systems, and SAP-based computerized warehouse management validated per 21 CFR Part 11.

Meiji Pharma Spain generates revenue through direct sales of its proprietary branded pharmaceuticals and medical devices via its own sales network in Spain, international export sales to more than 25 countries, tender participation for medicines and medical devices, and contract manufacturing for other multinational pharmaceutical companies. GTM is sales-led, targeting General Medicine, Gynecology, Traumatology, Ophthalmology, and Cardiovascular specialties, supported by a private healthcare-professional portal, medical sales representatives (Health Technical Informers), and adherence to Farmaindustria's self-regulatory transparency code. Pricing is not publicly disclosed; products are sold through commercial offers and tenders. The company is privately held with no external investors, and Roberto García Navalmoral serves as President and CEO.

Name

Meiji Pharma Spain

Legal name

Meiji Pharma Spain, S.A.

Website

https://meiji.es

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

251–500 employees

Short description

Meiji Pharma Spain is a Madrid-based pharmaceutical manufacturer and wholly-owned subsidiary of Japan's Meiji Seika Pharma, producing antibiotics, sterile injectables, hyaluronic acid medical devices, and hospital disinfection products at two GMP-certified (EU, US FDA, ANVISA, PMDA) plants and exporting to 25+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical manufacturing
• Prescription medicines
• Cephalosporin antibiotics
• Hyaluronic acid devices
• Hospital disinfection

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing and Export: Meiji Pharma Spain manufactures and exports pharmaceutical products including prescription medicines (antibiotics, cardiovascular, CNS, musculoskeletal) and medical devices (hyaluronic acid products, hospital disinfection) to more than 25 countries worldwide. Also manufactures products for other multinational pharmaceutical companies.
2. Proprietary Product Sales: Sales of in-house branded pharmaceutical products including Meiact (Cefditoren), Spectracef, Dagan (Zolpidem), Escitalopram, Lornoxicam, Presar (Valsartan), Profer, Vysribli (Denosumab), and hyaluronic acid medical devices (Adant, Viscoartro, Supralon).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Meiji Pharma Spain manufactures and exports a broad portfolio of prescription medicines — including cephalosporin antibiotics (Meiact/Spectracef), CNS, cardiovascular, anti-inflammatory, and iron-supplement generics — along with medical devices such as intra-articular and ophthalmic hyaluronic acid products and Class IIb hospital disinfection solutions. It operates two dedicated manufacturing plants under EU GMP, US FDA, ANVISA, PMDA, and ISO 13485 certifications and also performs contract manufacturing for multinational pharmaceutical companies, exporting to more than 25 countries.

Product overview

Meiji Pharma Spain operates as a pharmaceutical company offering a broad portfolio of prescription medicines and medical devices. The medicines portfolio includes generic drugs (EFG) covering antibiotics (Meiact/Spectracef with Cefditoren, Acyclovir), CNS medications (Dagan/Zolpidem, Escitalopram), anti-inflammatory (Lornoxicam), cardiovascular (Presar/Valsartan), and iron supplementation (Profer). The medical devices portfolio centers on hyaluronic acid products for intra-articular treatment of osteoarthritis (Adant One, Adant 2.5ml, Viscoartro) and ophthalmic surgery (Supralon 1%, 1.4%, 2%, 3% Dispersive), as well as hospital disinfection products (ADASPOR, PERASAFE, ISACLEAN, BACTRYL, VIRKON). The company exports to more than 25 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Adant: Intra-articular hyaluronic acid product line for osteoarthritis treatment, including Adant One (10mg/ml, 49mg), Adant 2.5ml (10mg/ml), and Viscoartro (20mg/ml, 98mg).
• Supralon
• ADASPOR
• PERASAFE
• ISACLEAN
• BACTRYL
• VIRKON

Products and services

• Adant One Sodium hyaluronate 10mg/ml, 49mg intra-articular injection for mild and moderate osteoarthritis and joint recovery following arthroscopic procedures; Class IIb medical device.
• Adant 2.5ml Sodium hyaluronate 10mg/ml intra-articular injection for osteoarthritis of the knee and painful shoulder, Grade I-III trapezoid-metacarpal osteoarthritis; Class IIb medical device.
• Viscoartro Sodium hyaluronate 20mg/ml, 98mg intra-articular injection indicated to reduce pain and lack of mobility due to degenerative and traumatic changes of the knee joint and other synovial joints associated with osteoarthritis; Class IIb medical device.
• Supralon 1% Viscoelastic, clear, colorless, sterile, isotonic ophthalmic viscosurgical device (OVD) for intraocular use during surgical procedures, maintaining depth of anterior chamber and protecting corneal endothelium; Class IIb medical device.
• Supralon 1.4% Ophthalmic viscosurgical device indicated as adjunct during surgical procedures involving the anterior chamber of the eye, particularly cataract surgery; Class IIb medical device.
• Supralon 2% Ophthalmic hyaluronic acid solution for intraocular surgical procedures; Class IIb medical device.
• Supralon 3% Dispersive Dispersive ophthalmic hyaluronic acid solution for intraocular surgical procedures; Class IIb medical device.
• ADASPOR Authentic Peracetic Acid cold sporicidal product for high-level instrument disinfection (Class IIb medical device).
• PERASAFE Peroxide powder system for elimination of spores in 1 minute (Class IIb medical device).
• ISACLEAN Four-enzymatic soap with descaling and disinfecting effect for instrument cleaning (Class IIb medical device).
• BACTRYL 2-in-1 cleaning and disinfection spray for instruments at intermediate level (Class IIb medical device).
• VIRKON Broad spectrum cleaning and disinfection powder for floors and environments (Class IIb medical device).
• Acyclovir Meiji Acyclovir 25 mg/ml solution for infusion EFG (generic prescription medicine).
• Dagan Zolpidem tartrate orodispersible tablets in 5 mg and 10 mg doses for insomnia treatment (EFG generic).
• Escitalopram Meiji Orodispersible tablets in 10 mg, 15 mg, and 20 mg doses for depression treatment (EFG generic).
• Lornoxicam Rapid Meiji 8 mg film-coated tablets for anti-inflammatory treatment (EFG generic).
• Meiact Cefditoren 200 mg and 400 mg film-coated tablets, a third-generation cephalosporin antibiotic.
• Presar Valsartan orodispersible tablets in 40 mg, 80 mg, 160 mg, and 320 mg doses for cardiovascular treatment (EFG generic).
• Profer Ferrimannitol ovalbumin 40 mg soluble tablets and granules for oral solution (40 mg and 80 mg) for iron supplementation.
• Spectracef Cefditoren 200 mg and 400 mg film-coated tablets for antibiotic treatment (third-generation cephalosporin).
• Vysribli Denosumab 60 mg solution for injection in pre-filled syringe for bone disease treatment.
• First biosimilar product First biosimilar product launched by Meiji Pharma Spain in May 2026, representing the company's entry into biosimilars.

Quantifiable outcome

• Products exported to more than 25 countries worldwide
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• FarmaindustriacoreStrategic or Co-development PartnerMeiji Pharma Spain adheres to Farmaindustria's Self-Regulatory System for transparency in value transfers to healthcare professionals and institutions. Committed to highest ethical standards in pharmaceutical industry with internal controls including Compliance Committee and ethical codes of conduct.
• Fundación SarabastallminorGTM or Marketing PartnerCollaboration in Hushé Project - international healthcare cooperation bringing medical care to remote Pakistani village. Meiji donates intra-articular hyaluronic acid for osteoarthritis treatment and ultrasound device. Project includes prevention, healthcare assistance, and training over 24 years of operation.
• REFORESTA MADRIDminorGTM or Marketing PartnerEnvironmental volunteering partnership for reforestation activities. Collaboration on reforestation of rural areas with environmental awareness focus. Aligns with UN 2030 Agenda SDGs 13 (Climate Action) and 15 (Life on Land).
• Cruz Roja EspañolaminorGTM or Marketing PartnerCollaboration on World Blood Donor Day initiatives, supporting blood donation awareness campaigns and healthcare solidarity efforts.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Samsung Bioepis: Biosimilar-focused biopharmaceutical company with multiple approved biosimilars across immunology and oncology. Comparable as a potential biosimilar competitor given Meiji Pharma Spain's May 2026 biosimilar launch and overlapping target markets.

Direct peers

• Almirall: Spanish pharmaceutical company focused on dermatology and specialty medicines, with EU manufacturing operations. Comparable on Spanish roots, EU-GMP manufacturing base, and specialty pharma positioning.
• Laboratorios Cinfa: Leading Spanish pharmaceutical manufacturer with broad generic and OTC portfolio, EU-GMP manufacturing, and significant hospital and pharmacy distribution. Comparable by geography, generic portfolio breadth, and integrated manufacturing-distribution model.
• Laboratorios Rovi: Spanish specialty pharmaceutical manufacturer with proprietary and generic injectable/specialty products. Most directly comparable Spanish peer by size, listed status, manufacturing footprint, and focus on sterile and specialty injectable formats.
• Anika Therapeutics: Specialty medical device company focused on hyaluronic acid-based intra-articular osteoarthritis treatments and ophthalmic surgical products. Directly comparable to Meiji Pharma Spain's Adant/Viscoartro (intra-articular) and Supralon (ophthalmic) franchises.
• STADA Arzneimittel: European-headquartered generic and specialty pharmaceutical manufacturer with multi-country presence and contract manufacturing capabilities. Comparable on European generic manufacturing footprint, multi-jurisdictional regulatory reach, and CDMO services.
• Laboratorios Normon: Spanish generic pharmaceutical manufacturer producing tablets, injectables, and sterile forms at EU-GMP plants. Comparable on geography, generic product mix, and sterile/oral solid manufacturing capabilities.
• Kern Pharma: Spanish-based generic pharmaceutical company manufacturing generic medicines across multiple therapeutic areas including antibiotics and CNS. Comparable on Spanish market presence, generics portfolio, and hospital tender business.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with broad therapeutic coverage and global manufacturing footprint. Comparable on generic FDF manufacturing, sterile injectable capabilities, and broad geographic export reach, though at vastly larger scale.
• Sandoz: Global generic and biosimilar pharmaceutical company (Novartis spin-off) with leading biosimilar portfolio. Comparable on generic FDF manufacturing plus the biosimilar segment Meiji Pharma Spain just entered.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meiji Pharma Spain